Miltenyi Biomedicine
Zhengyu Liu has a strong background in regulatory affairs, with experience in various therapeutic areas such as oncology, neurology, rare genetic disorders, autoimmune diseases, and more. Currently serving as the Vice President and Head of US Regulatory Affairs at Miltenyi Biomedicine, Zhengyu has also held significant roles at Regulatory Professionals, Idorsia Pharmaceuticals Ltd, LEO Pharma Inc. US, and Sandoz Pharmaceuticals. With a Ph.D. in Pharmacology from the University of Iowa College of Medicine, Zhengyu is a seasoned professional in the field of regulatory affairs.
This person is not in any offices
Miltenyi Biomedicine
2 followers
Miltenyi Biomedicine is a biopharmaceutical company that develops innovative cell and gene therapies. We are committed to bring cancer treatments and regenerative therapies to patients with unmet medical needs worldwide. We work in partnership with physicians and other healthcare providers to expand access to new therapies. Our clinical research program includes: CAR T, CAR NK, our proprietary Adapter CAR™ and induced pluripotent stem cells (iPSC) technologies. For more information, please visit our website at www.miltenyibiomedicine.com.